China Pharma (NYSE:CPHI – Get Free Report) and MindWalk (NASDAQ:HYFT – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.
Institutional & Insider Ownership
6.7% of MindWalk shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares China Pharma and MindWalk’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| China Pharma | -85.56% | -63.93% | -31.42% |
| MindWalk | -89.65% | -92.61% | -54.15% |
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| China Pharma | $3.99 million | 15.43 | -$3.08 million | ($0.55) | -2.76 |
| MindWalk | $11.24 million | 5.65 | -$21.69 million | ($0.22) | -6.18 |
China Pharma has higher earnings, but lower revenue than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than China Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
China Pharma has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for China Pharma and MindWalk, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| China Pharma | 0 | 0 | 0 | 0 | 0.00 |
| MindWalk | 1 | 1 | 2 | 1 | 2.60 |
MindWalk has a consensus target price of $5.00, indicating a potential upside of 267.65%. Given MindWalk’s stronger consensus rating and higher probable upside, analysts plainly believe MindWalk is more favorable than China Pharma.
Summary
MindWalk beats China Pharma on 8 of the 15 factors compared between the two stocks.
About China Pharma
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People’s Republic of China.
About MindWalk
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
